A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis

LUO Jurui; CHEN Xingxing; YANG Zhaozhi

doi:10.19401/j.cnki.1007-3639.2018.10.008

您当前的位置：

首页 >

文章列表页 >

A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis

更新时间：2026-01-27

- A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis
- China Oncology Vol. 28, Issue 10, Pages: 769-775(2018)
- 作者机构：
  
  复旦大学附属肿瘤医院放疗科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.10.008
  CLC：
- Published Online：12 November 2018，
  
  Published：12 November 2018
- 稿件说明：
移动端阅览
罗菊锐,陈星星,杨昭志,等. 早期乳腺癌保乳术后大分割放疗Ⅱ期临床研究——中期安全性及有效性分析[J]. 中国癌症杂志, 2018, 28(10): 769-775.

LUO Jurui, CHEN Xingxing, YANG Zhaozhi. A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis[J]. China Oncology, 2018, 28(10): 769-775.
罗菊锐,陈星星,杨昭志,等. 早期乳腺癌保乳术后大分割放疗Ⅱ期临床研究——中期安全性及有效性分析[J]. 中国癌症杂志, 2018, 28(10): 769-775. DOI： 10.19401/j.cnki.1007-3639.2018.10.008.

LUO Jurui, CHEN Xingxing, YANG Zhaozhi. A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis[J]. China Oncology, 2018, 28(10): 769-775. DOI： 10.19401/j.cnki.1007-3639.2018.10.008.

摘要

背景与目的：乳腺癌保乳术后全乳大分割放疗的安全性和有效性在多项随机临床试验中已经得到证实，但全乳大分割瘤床同期加量的放疗模式目前仍不明确。本研究旨在探讨中国人群早期乳腺癌保乳术后大分割放疗同期瘤床加量的安全性及有效性。方法：前瞻性入组保乳术后切缘阴性、病理诊断为浸润性癌、分期pT

1-2

、术中瘤床钛夹标记的患者接受全乳大分割同期瘤床加量放疗（ClinicalTrail.gov: NCT02617043）。放疗处方剂量为全乳计划靶体积（planned target volume，PTV） 40 Gy/15次/3周，同期瘤床加量至48 Gy/15次/3周。放疗后评估急性不良反应、美容效果以及预后。结果：2015年1月—2016年8月，共计358例患者前瞻性连续性入组本研究。患者中位年龄45岁（25~71岁），71.2%（255例）为绝经前的年轻女性，其中T1和T2患者分别为276例（77.1%）和82例（22.9%）。放疗期间及放疗后3个月内，53.6%和8.1%的患者出现Ⅰ~Ⅱ度的放射性皮炎，主要表现为放疗区红斑（38.8%）以及放疗后干性脱皮（41.3%）。13例（3.6%）患者出现湿性脱皮，主要位于乳头、乳晕区，无Ⅲ度以上放射性皮炎。4例Ⅰ度放射性肺炎，1例Ⅲ度放射性肺炎。美容效果自评“极好”和“好”率分别为37.0%和44.8%。中位随访28.3个月（6.0~40.7个月），3例患者出现局部区域复发，4例远处转移（2例合并复发），2年无病生存率（disease-free survival，DFS）为98.6%。结论：对于早期乳腺癌保乳术后患者，全乳大分割同期瘤床加量放疗不良反应轻、耐受性好，具有一定的安全性及有效性，其晚期不良反应以及对疾病局部控制的有效性仍需长期随访来证实。

Abstract

Background and purpose: The long-term safety and efficacy of hypofractionated whole-breast irradiation (HFWBI) have been well established in randomized trials

but little is known about the effect of HF-WBI with simultaneous boost of the tumor bed. This study aimed to assess the safety and efficacy of HF-WBI with simultaneous tumor bed boost afte

r breast-conserving surgery in Chinese population. Methods: Patients with pT

1-2

invasive breast cancer

negative margins

clips marked tumor bed after breast-conserving surgery were prospectively and consecutively enrolled in this study. All patients received total dose of 40 Gy/15 Fx/3 weeks for whole breast

combined with simultaneous boost of tumor bed

total dose of 48 Gy/15 Fx/3 weeks. The acute radiotherapy-induced toxicities

cosmetic effect and prognosis were followed up after the treatment. Results: From Jan. 2015 to Aug. 2016

358 patients were enrolled in the study. The median age was 45 years (range

25-71 years)

and 71.2% patients were premenopausal young women. A total of 276 (77.1%) patients had T1 tumors

and 82 (22.9%) patients had T2. During the treatment

53.6% and 8.1% patients had Grade 1 and Grade 2 radiation dermatitis

respectively

mainly manifested as skin erythema (38.8%) or desquamation (41.3%). Thirteen patients experienced moist desquamation mainly in the nipple and areola area. No grade≥3 radiation dermatitis was observed. Four patients had Grade 1 and one patient had Grade 3 radiation pneumonitis. 37.0% and 44.8% patients’ self-assessed cosmetic effects were “Excellent” and “Good”

respectively. With a median follow-up time of 28.3 months (range: 6.0-40.7 months)

three patients experienced locoregional recurrence and four patients had distant metastasis (two of them with locoregional recurrence). The 2-year disease-free survival was 98.6%. Conclusion: Hypofractionated whole-breast irradiation combined with simultaneous boost of the tumor bed has few acute toxic effects and can be well tolerated in patients with early stage breast cancer after breast-conserving surgery. Long-term follow-up is needed to confirm its late toxic effects and efficacy of disease control.

关键词

Keywords

references

Views

2976

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expression of miR-6775-3p in breast cancer cells and its effect on biological behavior of breast cancer cells

Expression of circular RNA hsa_circ_0050900 in breast cancer and its effect on cell function

Correlation between imaging features and molecular subtypes in very young women with breast cancer

Evaluation of the effect of anthracyclines on left ventricular function in breast cancer patients using two- dimensional speckle tracking imaging combined with myocardial work

Research progress of breast tumor microenvironment-targeted therapy

Related Author

QI Zheng

XUE Yun

LI Zongliang

ZHANG Xiaochong

LEI Qiuxiang

ZHANG Ti

JING Lihong

LIU Dengxiang

Related Institution

邢台市人民医院检验科

邢台市第三医院检验科

邢台市人民医院核医学科

邢台市人民医院美容科

巨鹿县卫生学校内科

AI问答

⁰